Alnylam Pharmaceuticals, Inc. (FRA:DUL)
Germany flag Germany · Delayed Price · Currency is EUR
285.30
-2.10 (-0.73%)
At close: Feb 20, 2026

Alnylam Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
313.75-278.16-440.24-1,131-852.82
Depreciation & Amortization
55.6656.6754.0544.4789.69
Loss (Gain) From Sale of Investments
2.313.0216.9433.31-55.7
Stock-Based Compensation
348.24272.08221.68230.65165.72
Other Operating Activities
248.92152.15194.46273.84174.24
Change in Accounts Receivable
-359.96-86.55-87.94-45.6-101.8
Change in Inventory
8.4713.5918.37-34.14-26.42
Change in Accounts Payable
75.0791.0980.84191.7788.24
Change in Unearned Revenue
-50.64-235.4555.02-65.91-50.4
Change in Other Net Operating Assets
-117.723.23-9.03-38.51-72.45
Operating Cash Flow
524.08-8.31104.16-541.27-641.69
Capital Expenditures
-58.7-34.28-62.21-72.06-76.37
Investment in Securities
497.18-63.25-269.7254.61-192.56
Other Investing Activities
-2.15-19.32-4.44-13.19-4.36
Investing Cash Flow
436.33-116.84-336.35169.35-273.3
Long-Term Debt Issued
645.69--1,016500
Long-Term Debt Repaid
-1,193---880.72-
Net Debt Issued (Repaid)
-546.95--135.39500
Issuance of Common Stock
250.03302.95147.46259.36246.27
Other Financing Activities
-8.27-8.7924.6731500.85
Financing Cash Flow
-305.19294.16172.13425.751,247
Foreign Exchange Rate Adjustments
34.94-15.246.39-7.43-9.02
Net Cash Flow
690.16153.77-53.6746.4323.11
Free Cash Flow
465.38-42.5941.95-613.33-718.07
Free Cash Flow Margin
12.53%-1.89%2.29%-59.12%-85.05%
Free Cash Flow Per Share
3.46-0.330.34-5.04-6.06
Cash Interest Paid
218.7167.5832.1245.2424.66
Cash Income Tax Paid
21.29.312.572.65-
Levered Free Cash Flow
128.79197.88103.55-444.3597.11
Unlevered Free Cash Flow
286.68286.54179.32-346.87186.5
Change in Working Capital
-444.78-214.0857.267.62-162.82
Source: S&P Global Market Intelligence. Standard template. Financial Sources.